News | Proton Therapy | October 25, 2020

Penn study presented today at ASTRO20 shows potential cardiac benefit with protons versus photons

Treating lung cancer patients with proton therapy may help reduce the risk of radiation-induced heart diseases, suggests a new study from Penn Medicine. In a retrospective trial of more than 200 patients, mini-strokes were significantly less common among patients who underwent proton therapy versus conventional photon-based radiation therapy. Proton therapy patients also experienced fewer heart attacks.

October 25, 2020 — Treating lung cancer patients with proton therapy may help reduce the risk of radiation-induced heart diseases, suggests a new study from Penn Medicine. In a retrospective trial of more than 200 patients, mini-strokes were significantly less common among patients who underwent proton therapy versus conventional photon-based radiation therapy. Proton therapy patients also experienced fewer heart attacks.

Timothy Kegelman, M.D., Ph.D., chief resident in the department of Radiation Oncology in the Perelman School of Medicine at the University of Pennsylvania, presented the findings on Sunday, October 25, at the American Society for Radiation Oncology virtual Annual Meeting (Abstract #1046).

"This shows us another potential benefit of proton therapy for lung cancer patients," Kegelman said. "We know proton has the ability to minimize radiation doses to surrounding organs like the heart. And these latest findings suggest that sparing correlates with fewer cardiac problems compared to conventional therapy."

Abigail T. Berman, M.D., MSCE, as assistant professor of Radiation Oncology at Penn, serves as senior author on the study.

Cardiac toxicity from radiation therapy remains a significant concern for lung cancer patients. One strategy to minimize dose is the use of proton therapy, which has the ability to more precisely target tumors and spare adjacent vital organs and healthy tissue.

The study found that 1.1 percent of patients with locally advanced non-small cell lung cancer treated with proton therapy experienced post-treatment mini-strokes, also known as transient ischemic attacks, after a median follow up of 29 months compared to 8.2 percent of patients treated with photon radiation therapy. Myocardial infarctions were also less common in the proton therapy group compared to the photon group, though the difference was not statistically significant: 2.3 percent versus nine percent.

There was no difference in the number of cases of atrial fibrillation, coronary artery disease, heart failure, or stroke. The researchers continue to compare the two approaches by looking more closely at the severity of the cardiac events and radiation dose to specific parts of the heart. The analysis will help radiation oncologists have a better understanding of how to minimize these risks further with newer technologies.

A large prospective, international phase III clinical trial investigating the difference between proton therapy and photon therapy in lung cancer patients--which includes patients treated in Penn's Roberts Proton Therapy Center--has also been underway since 2014. The expectation is that protons will reduce cardiac-related morbidity and mortality, which will translate into a higher cure rate, the authors said. The trial is expected to complete patient accrual in 2022.

This study is the first experience suggesting a benefit of proton therapy over intensity modulated radiotherapy, or IMRT, in reducing cardiac dose effects.

"While these findings are promising and add to growing evidence, more research and the results of the randomized trial will help us better determine and understand how treating with protons may reduce cardiac event risk," Kegelman said.

For more information: pennmedicine.org

Related Content

News | PET Imaging

October 18, 2021 — PSMA (prostate-specific membrane antigen) PET/CT is more accurate than conventional CT in the ...

Time October 18, 2021
arrow
News | Ultrasound Women's Health

October 14, 2021 — In a first-in-world clinical trial, researchers at Sunnybrook Health Sciences Centre in Toronto ...

Time October 14, 2021
arrow
News | Lung Imaging

October 11, 2021 — According to ARRS’ American Journal of Roentgenology (AJR), percutaneous image-guided microwave and ...

Time October 11, 2021
arrow
News | Quality Assurance (QA)

October 11, 2021 — To maintain safety in radiation therapy (RT), every machine performance and patient delivery ...

Time October 11, 2021
arrow
News | Women's Health

October 8, 2021 — An analysis of nearly 200,000 patients who received mammograms between 2006 and 2015 across three U.S ...

Time October 08, 2021
arrow
News | Radiation Therapy

October 7, 2021 — NANOBIOTIX, a late-stage clinical biotechnology company pioneering physics-based approaches to expand ...

Time October 07, 2021
arrow
News | Radiation Therapy

October 7, 2021 — ViewRay, Inc. announced that the company has received acceptance from the FDA on their recent ...

Time October 07, 2021
arrow
Feature | Cardiac Imaging

October 6, 2021 – A new study published in Radiology: Cardiothoracic Imaging on cardiac imaging trends over a decade ...

Time October 06, 2021
arrow
News | Women's Health

October 5, 2021 — A promising radionuclide treatment may offer new therapeutic options for breast cancer patients ...

Time October 05, 2021
arrow
Feature | Radiation Therapy | By Dave Fornell

To maintain safety in radiation therapy (RT), every machine performance and patient delivery measurement must be as ...

Time October 05, 2021
arrow
Subscribe Now